The diagnosis of cardiovascular diseases (CVDs), including AMI, is based on a combination of clinical findings, electrocardiogram, and serum biomarkers. AMI is caused by ischemia in the cardiac vasculature, leading to necrosis of the affected area. AMI accounts for almost half of all CVDs globally, indicating the seriousness of the disease. Several salivary biomarkers have been identified in the literature that can aid in the diagnosis of cardiovascular diseases (CVDs). These include Myoglobin (MYO), Cardiac troponin I (cTnI), Creatine phosphokinase MB (CK-MB), Myeloperoxidase (MPO), brain natriuretic peptide (NT-proBNP), Exosomal miRNA, C-Reactive Protein (CRP), Matrix metalloproteinase-8 (MMP-8), MMP-9, and tissue inhibitor of MMP-8 (TIMP-1). These biomarkers are important for early diagnosis of CVDs and can be detected in saliva, making it a non-invasive, cost-effective, and easily accessible sample for testing.